Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107874851/en/
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors. (Graphic: Business Wire)
This collaboration combines Biocytogen’s RenLite® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology to tackle some of the toughest challenges in oncology—tumor heterogeneity and drug resistance. This novel approach aims to address these complexities by utilizing dual-payloads that target multiple therapeutic or disease pathways. These payloads are delivered with bispecific antibodies that enable enhanced precision and functionality.
As part of the strategic partnership, Biocytogen will provide a bispecific antibody derived from its proprietary RenLite® platform, which is designed to produce fully human bispecific antibodies with unique binding properties. To this antibody, Acepodia will integrate two different payloads using its Antibody-Dual-Drugs Conjugation (AD2C) platform. This platform enables site-selective conjugation of multiple payloads to an antibody using bio-orthogonal click chemistry with no required antibody engineering, maintaining antibody integrity and binding capacity, and allowing strategic and precise control over the Drug-to-Antibody Ratio (DAR) for optimal potency and safety.
“We are thrilled to partner with the Acepodia team who brings deep expertise in bio-orthogonal click chemistry and the unique opportunity to combine our RenLite® bispecific antibodies with site-selective dual-payload conjugates,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “We look forward to bridging our platforms to explore the therapeutic potential of highly potent BsADCs.”
“Biocytogen’s superior bispecific antibodies and highly collaborative team make them an ideal partner for advancing our AD2C payload platform,” said Sonny Hsiao, Ph.D., Co-Founder and CEO of Acepodia. “This partnership redefines the possibilities of ADC design, with the potential to deliver breakthrough therapies to patients in desperate need of new options.”
This strategic partnership underscores the commitment of both companies to addressing the critical unmet needs in ADC drug development for solid tumors, paving the way for innovative therapies that improve patient outcomes
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About Acepodia
Acepodia is transforming cancer and autoimmune disease treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia’s platforms are designed to improve safety and offer broad applicability across hematologic and solid tumor cancers, as well as autoimmune diseases. By combining innovative science with a patient-centric vision, Acepodia aims to bring powerful, next-generation therapies to patients underserved by today’s treatments. For more information, please visit https://www.acepodia.com/.
Forward-Looking Statements
This press release contains forward-looking statements regarding the potential therapeutic benefits, evaluation outcomes, and future development strategies for the dual-payload BsAD2C program. Such statements are subject to risks and uncertainties that may cause actual results to differ materially. Neither Biocytogen nor Acepodia undertakes any obligation to update these forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107874851/en/
Contacts
Media: pr@bbctg.com.cn
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Recognized as AIT Fraud Prevention Leader by Juniper Research9.1.2025 10:01:00 CET | Press Release
Global cloud communications platform Infobip has been recognized as the number one provider among Established Leaders in the Artificially Inflated Traffic (AIT) Fraud Prevention market by Juniper Research. The analyst firm has ranked Infobip first of 18 vendors in its Competitor Leaderboard for AIT Fraud Detection Solution Vendors 2024. Juniper Research scores vendors across 11 criteria, including but not limited to their size of operations in the AIT prevention market, the extent and breadth of relevant partnerships, market coverage, and product strength. Infobip scored highly across each of these and three further categories. Overall, Infobip was ranked as the Leading firm because it offers a comprehensive solution to AIT fraud detection and prevention strategies, including its ‘Infobip Signals’ solution, which detects AIT by monitoring phone number behavior, ranges, and types. Helping set Infobip aside from others in the market is its use of artificial intelligence (AI) and machine
Northleaf Completes Investment in CCM Hockey alongside Altor Equity Partners9.1.2025 10:00:00 CET | Press Release
Northleaf Capital Partners (“Northleaf”), a global private markets investment firm, today announced that funds under its management have completed an investment in CCM Hockey (“CCM” or “the Company”). Northleaf partnered with Altor Equity Partners (“Altor”), a leading European middle-market private equity firm, to acquire the business. Financial terms of the transaction were not disclosed. Founded in 1899, CCM is a leading designer, manufacturer, and distributor of hockey equipment, including sticks, skates, protective gear, helmets, goalie equipment, and apparel. Headquartered in Montreal, Canada, the Company operates in more than 40 countries and is represented by many NHL and PWHL superstars. “Northleaf is proud to be a part of Canadian hockey history and support CCM’s next stage of growth, alongside a trusted mid-market sponsor like Altor,” said Michael Flood, Head of Private Equity at Northleaf. “CCM’s iconic brand and strong industry tailwinds, coupled with Altor’s deep consumer
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy9.1.2025 09:00:00 CET | Press Release
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for thetreatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway). This approval of the extension of indication of Palforzia® to toddlers, follows the July 2024 approval by the U.S. Food and Drug Administration (FDA). Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy. “Peanut allergy is one of the most frequent food allergies. Early intervention is crucial to reduce the risks of accidental exposure and may be very important in improving long-term outcomes. The approval of Palforzia for toddl
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference9.1.2025 08:37:00 CET | Press Release
Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann Pick type C (NPC). Positive topline data reported earlier this year from the company’s successful Phase 2 study investigating nizubaglustat in GM2 and NPC patients demonstrated that the compound had a positive safety profile. Preliminary improvements or stabilization of clinical endpoints were observed in the majority of patients, highlighting encouraging early efficacy trends for the compound. Azafaros is preparing to initiate Phase 3 studies with nizubaglustat in
Kaneka Acquires EndoStream Medical Ltd.9.1.2025 06:21:00 CET | Press Release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) acquired 96.8% of shares of EndoStream Medical Ltd. (Headquarters: Or Akiva, Israel; CEO: Danel Mayer; hereinafter referred to as ESM), an Israeli medical equipment company, on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus™ device for aneurysm treatment currently under development. We aim to achieve sales of over 20 billion yen by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108226003/en/ Cerebral aneurysm treatment device “Nautilus™” (Graphic: Business Wire) ESM is a manufacturer of innovative technologies in the field of cerebrovascular diseases and is developing a device for the treatment of cerebral aneurysms called “Nautilus™” that can treat aneurysms with wide openings in cerebr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom